15 Feb

Roche to Acquire Cancer Software Startup Flatiron Health for $1.9B

Roche has agreed to acquire Flatiron Health for $1.9 billion, a deal that brings the cancer research capabilities of Flatiron to the oncology drug portfolio and pipeline of the pharmaceutical giant.

Roche already owns a 12.6 percent stake in Flatiron. The Basel, Switzerland company expects to complete the acquisition of the remaining Flatiron shares in the first half of this year.

Flatiron, based in New York, makes cancer-specific electronic health record software. The data that the Flatiron software collects-stripped of patient-identifying information-is sold to drug companies and others to use in research, as well as for fine-tuning clinical trial recruitment. Flatiron… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

15 Feb

Research Headlines – Tackling big data challenges in shades of grey

[Source: Research & Innovation] EU-funded researchers have assisted in the development of China’s first commercial passenger plane by applying data mining concepts that overcome the challenge of working with limited and incomplete information.

15 Feb

ICYMI: Insights from my time with Vicki Sato at BIO CEO & Investor Conference

At this week’s BIO CEO & Investor Conference the idea of saving the “best for last” certainly did apply. I had the great pleasure of moderating the final fireside chat with Vicki Sato, Chairman of Denali Therapeutics and Vir Biotechnologies, and co-Chair of Mayor de Blasio’s Life Sciences Advisory Council. Vicki’s career journey in the life sciences industry is as diverse as it is impressive, and she opened up to the audience about just a few of the successes and challenges she’s encountered along the way.

In case you missed it live, I’m sharing my top 3 takeaways from this raw and inspiring session:

The life sciences/biotech industry wouldn’t exist without people who are willing to take tremendous risk.

This industry has been built on taking major risks not only in science, but also from a business and financial perspective. A persistent belief in yourself that you can always do better and taking those tough challenges on, that while ridiculous to some, are equally irresistible.

Vicki’s current risk of choice? Getting involved with companies who are focused on some of the most complex healthcare challenges of our time, including Hepatitis C and Cystic Fibrosis. “If someone doesn’t take on these diseases we won’t improve the rate of progress against them… I feel I have a scientific and moral obligation to get involved.”

New York City is ripe for “irresistible risk taking” in this industry.

NYC is already a hub for biomedical innovation – an epicenter for academia, medical institutions and both private and public funding at your fingertips. 

The city and state are now providing incentives to keep healthcare innovation companies local, versus moving to the likes of Boston or Silicon Valley, and progress is being made a rate faster than ever to make the necessary adjustments to other perceived bottlenecks, such as challenging zoning laws and expensive rent.

All the more reason we are thrilled to be partnering with the state to open the doors to our JLABS @ NYC site in June of this year!

Diversity, in all senses of the word, is critical in this business.

Cultivating a culture of diversity and inclusion in the life sciences industry was a major topic at this year’s conference. Vicki highlighted that diversity certainly impacts the bottom line of business, emphasizing that in her experience it hasn’t been necessarily “in the labs” where we’re lacking. The challenge lies in maintaining that diversity at the management and board level, especially when it comes to gender disparity.

She highlighted that diversity of ALL kinds is impactful, beyond the traditional definition. Diverse management skills, such as the ability to raise significant quantities of funding on a sustainable basis, are also key when we think about influencing this industry.

It’s conversations like this that remind me why I’m so proud to be a part of a company that is passionate about these issues. While we’ve come a long way in NYC, it’s going to take banding together as a community to ensure we’re moving the needle and enabling this ecosystem to thrive.

15 Feb

Russian trolls flood Twitter after Parkland shooting

Without identification by Twitter or the government, it’s impossible to know who is a troll and who isn’t. A survey of tweets using the top hashtags flagged by the Hamilton 68 dashboard showed tweets adamantly in favor of gun control and saying the NRA had taken “blood money.” Other tweets attacked …

15 Feb

Stratatech Begins Test of Engineered Skin for Diabetic Foot Ulcers

Stratatech is moving forward with tests of a genetically engineered human skin that could heal the sores and wounds many diabetic patients get on their feet.

Madison, WI-based Stratatech, a subsidiary of U.K.-based Mallinckrodt (NYSE: MNK), said Wednesday that it had enrolled the first patient in a study of the skin tissue, called ExpressGraft-C9T1.

Stratatech said the ExpressGraft skin tissue builds on some of the same technologies the company pioneered in developing StrataGraft, its flagship skin replacement product. StrataGraft is cell-based skin tissue designed to coax the bodies of burn patients into regenerating skin.

The trial Stratatech announced on… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

14 Feb

FDA O.K.’s Banyan Diagnostic, the First Blood Test for Concussions

The FDA has approved the first blood test to help diagnose concussions, clearing a path to the market for a diagnostic that could reduce the use of expensive brain imaging technologies that expose patients to radiation.

The approval goes to San Diego diagnostics developer Banyan Biomarkers. The company’s test, called Banyan BTI (short for brain trauma indicator), measures the levels of two proteins that the brain releases into the blood in the hours following a head injury. The company developed the test with partial support from a contract with the U.S. Army.

The current standard for concussion diagnosis involves a neurological… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

14 Feb

2nd HBP Curriculum Workshop Series – ENTREPRENEURSHIP IN NEUROSCIENCE – TURNING SCIENCE INTO INVEN – 4-6 July 2018, Berlin, Germany

[Source: Research & Innovation] This “hackathon” style workshop is a hands-on intensive experience complementing the theoretical aspects of the online course on Intellectual Property Rights, Translation and Exploitation of Research.
Students will work in small multi-disciplinary teams to assemble joint applied research proposals in the wide range of fields in brain science.
Experienced entrepreneurs, top executives at the interface between academia and industry and researchers from academia will present, mentor and advise on the translational aspects of the offered projects including how to advance their proposal from the lab to market, understand the problems and accordingly defining the needs in the chosen field, choosing or identifying the target population, patentability options and how to build a business model.
Finally, they will present their proposals to industry and academy experts. The workshop is a unique experience of diving into the entrepreneurial world, learning how to incorporate innovation and entrepreneurship mindset and concepts into day-to-day research work and beyond.

14 Feb

Happy Valentine’s Day: Biotechnology is Good for the Heart

With today being Valentine’s Day and February being American Heart Month, there’s no better time to explore how biotechnology has benefited one of mankind’s most vital organs, the heart.

Question: When was the first American Heart Month? (read to see answer below)

On Valentine’s Day we may view the heart as a representation of love and joyfulness, but heart complications have plagued man for some time. According to the American Heart Association, in the 1960s more than half of the deaths in the U.S. were caused by cardiovascular disease. Today, heart disease is still the leading cause of death with more than 17.9 million people succumbing to the disease each year. In the future, that number is only expected to go up.

So, where does biotechnology come into play?  Well, as you probably are aware, one of the best nutrients to improve heart health is a type of fatty acid known as Omega-3. Omega-3s cannot be manufactured, so the best place to get them is through your diet. Using biotechnology, we can enhance Omega-3-rich foods to increase their availability and nutritional value.

Canola

Arguably one of the most popular oils at your local supermarket, canola oil is high in Omega-3 fatty acids. Coupled with the fact that the oil is widely used, canola oil is a common source of Omega-3s for many. Therefore, the availability of the canola plant is critical. So, to increase supply of the crop, scientists modified the canola plant to carry a trait that makes it herbicide resistant.  Before this intervention, the canola plant was highly susceptible to weeds. Farmers were forced to till the soil between yields to disrupt the growth of the weeds and protect the crops. By growing herbicide resistant canola, however, this tilling process in no longer necessary. This saves farmers both time and money and provides more time for the crop to reach its full yield potential, thus increasing crop yields and canola oil production. Because of biotechnology, canola oil is a food item that consumers can rely on to consume Omega-3s and improve heart health.

Soybean

Found in many products such as milk, oils and proteins, soybean is another popular crop that already has high levels of Omega-3 fatty acids. Thanks to biotechnology, however, scientists were able to increase the amount of Omega-3s in the crop. In 2009, the FDA ruled that soybeans modified to contain increased levels of Omega-3s are safe for human consumption and, as a result, could start serving as a substitute for other sources of the essential fatty acid.  Today, the crop is seen as a viable source of Omega-3s.

Salmon

Researchers have already made progress on improving other sources of Omega-3s, such as meats and seafood, using biotechnology. One example is the salmon, a well-known source of Omega-3s. Through biotechnology, researchers have created the AquAdvantage salmon, which grows to market size faster than conventional salmon. Once this fish hits the market, the supply of the nutrient-rich fish will likely increase, resulting in another heart-healthy food that consumers can rely on.

With the rate of heart disease not slowing down, we’ll need to continue looking at ways to improve crops, like canola and soybean, and meats and seafood, like salmon, to ensure we maintain a steady supply of Omega-3-rich foods.

Answer: In December 1963, then-President Lyndon Johnson proclaimed February as American Heart Month. The following February (1964) marked the first recognition of American Heart Month, which has been recognized every year since.

14 Feb

iShares NASDAQ Biotechnology Index (IBB) Position Increased by Evanson Asset Management LLC

iShares NASDAQ Biotechnology Index logo Evanson Asset Management LLC grew its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 197.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,702 shares of the …

13 Feb

FDA’s Rachel Sherman on Right to Try, Succession Trouble & More

The opioid crisis. Right to Try legislation. The first human trials of CRISPR-Cas9 gene editing technology. These are just a few of the many topics at the feet of the FDA this year.

Speaking at the BIO CEO & Investor Conference in New York on Tuesday, principal deputy commissioner Rachel Sherman, the FDA’s second in command to commissioner Scott Gottlieb, fired through a variety of issues affecting the agency both now and in the future.

Here are just a few tidbits from the chat, moderated by Biotechnology Industry Organization president and CEO Jim Greenwood.

Right to Try

A Republican-led push is… Read more »

UNDERWRITERS AND PARTNERS